Xiaomin Liu

Xiaomin Liu

Auto-generated profile, based on publicly available information

Xiaomin Liu

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics National Institute of Diagnostics and Vaccine Development in Infectious Diseases National Innovation Platform for Industry‐Education Integration in Vaccine Research School of Public Health School of Life Sciences Xiamen University Xiamen 361102 P.R. China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Science Advances
Verified
Journal Article
Closed access
FZFantian Zeng
Fantian Zeng
SNSureya Nijiati
Sureya Nijiati
YLYangtengyu Liu
Yangtengyu Liu
QYQinqin Yang
Qinqin Yang
XLXiaomin Liu
Xiaomin Liu
ZZZijian Zhou
Zijian Zhou
Ferroptosis has been realized in anticancer drug–induced acute cardiac/kidney injuries (ACI/AKI); however, molecular imaging approach to detect ferroptosis in ACI/AKI is a challenge. We report an artemisinin-based probe (Art-Gd) for contrast-enhanced magnetic resonance imaging of ferroptosis (feMRI) by exploiting the redox-active Fe(II) as a vivid chemical target. In vivo, the Art-Gd probe showed great feasibility in early diagnosis of anticancer drug–induced ACI/AKI, which was at least 24 and 48 hours earlier than the standard clinical assays for assessing ACI and AKI, respectively. Furthermore, the feMRI was able to provide imaging evidence for the different mechanisms of action of ferroptosis-targeted agents, either by blocking lipid peroxidation or depleting iron ions. This study presents a feMRI strategy with simple chemistry and robust efficacy for early evaluation of anticancer drug–induced ACI/AKI, which may shed light on the theranostics of a variety of ferroptosis-related diseases.

1 July 2020 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
LSLi Sun
Li Sun
XLXiao-Min Liu
Xiao-Min Liu
WLWen-Zhu Li
Wen-Zhu Li
YYYuan-Yuan Yi
Yuan-Yuan Yi
XHXiangwei He
Xiangwei He
QJQuan-Wen Jin
Quan-Wen Jin
In the fission yeast Schizosaccharomyces pombe, both RNAi machinery and RNAi- independent factors mediate transcriptional and posttranscriptional silencing and heterochromatin formation. Here, we show that the silencing of reporter genes at major native heterochromatic loci (centromeres, telomeres, mating-type locus and rDNA regions) and an artificially induced heterochromatin locus is alleviated in a fission yeast hsp90 mutant, hsp90-G84C. Also, H3K9me2 enrichment at heterochromatin regions, especially at the mating-type locus and subtelomeres, is compromised, suggesting heterochromatin assembly defects. We further discovered that Hsp90 is required for stabilization or assembly of the RNAi effector complexes RITS and ARC, RNAi-independent factor Fft3, shelterin complex subunit Poz1 and SHREC. Our ChIP data suggest that Hsp90 regulates the efficient recruitment of CLRC by shelterin to chromosome ends and targeting of SHREC and Fft3 to mating type locus and/or rDNA region. Finally, our genetic analyses demonstrated that increased heterochromatin spreading restores silencing at subtelomeres in hsp90-G84C mutant. Thus, this work uncovers a conserved factor critical for promoting RNAi-dependent and -independent heterochromatin assembly and gene silencing through stabilizing multiple effectors and effector complexes.

11 February 2024 in Advanced Science
Verified
Journal Article
Open access
YJYichao Jiang
Yichao Jiang
XCXiaoqing Chen
Xiaoqing Chen
XYXinya Ye
Xinya Ye
CWCan Wen
Can Wen
TXTao Xu
Tao Xu
NXNingshao Xia
Ningshao Xia
Chronic hepatitis B (CHB) remains a major public health concern because of the inefficiency of currently approved therapies in clearing the hepatitis B surface antigen (HBsAg). Antibody‐based regimens have demonstrated potency regarding virus neutralization and HBsAg clearance. However, high dosages or frequent dosing are required for virologic control. In this study, a dual‐domain‐engineered anti‐hepatitis B virus (HBV) therapeutic antibody 73‐DY is developed that exhibits significantly improved efficacy regarding both serum and intrahepatic viral clearance. In HBV‐tolerant mice, administration of a single dose of 73‐DY at 2 mg kg −1 is sufficient to reduce serum HBsAg by over 3 log 10 IU mL −1 and suppress HBsAg to < 100 IU mL −1 for two weeks, demonstrating a dose‐lowering advantage of at least tenfold. Furthermore, 10 mg kg −1 of 73‐DY sustainably suppressed serum viral levels to undetectable levels for ≈ 2 weeks. Molecular analyses indicate that the improved efficacy exhibited by 73‐DY is attributable to the synergy between fragment antigen binding (Fab) and fragment crystallizable (Fc) engineering, which conferred sustained viral suppression and robust viral eradication, respectively. Long‐term immunotherapy with reverse chimeric 73‐DY facilitated the restoration of anti‐HBV immune responses. This study provides a foundation for the development of next‐generation antibody‐based CHB therapies.